Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$322M+43.8% YoY

Gross Profit

$203M63.0% margin

Operating Income

$124M38.6% margin

Net Income

$94M29.3% margin

EPS (Diluted)

$1.33

QoQ Revenue Growth

+7.0%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$43M

Stock-Based Comp.

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$785M

Stockholders' Equity

$553M

Cash & Equivalents

$414M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$322M	$224M	+43.8%
Gross Profit	$203M	$138M	+46.8%
Operating Income	$124M	$63M	+96.4%
Net Income	$94M	$43M	+118.6%

Revenue Segments

Product

$314M33%

Radiopharmaceutical Oncology

$211M22%

PYLARIFY

$211M22%

Total Precision Diagnostics

$98M10%

DEFINITY

$71M7%

Techne Lite

$22M2%

Strategic Partnerships And Other

$13M1%

License and Royalty Revenues

$8M1%

Other Precision Diagnostics

$5M1%

Other Radiopharmaceutical Oncology

$818,0000%